The nonstaff members of IAS–USA Resistance Testing Guidelines Panel are volunteers and are not compensated for their role in overseeing the program. Listed below are the IAS–USA Resistance Testing Guidelines Panel members and their financial relationships with commercial interests within the past 12 months from the date of disclosure.


Huldrych F. Günthard, MD
Professor of Infectious Diseases
University Hospital Zurich
Zurich, Switzerland

Dr Günthard has served as a consultant to Merck & Co, Inc, ViiV Healthcare, Sandoz, Teva, and Gilead Sciences, Inc and received research grants from the Swiss National Science Foundation, Systems.X (HIV.X), Swiss HIV Cohort Study, the Yvonne Jacob Foundation, and Gilead Sciences, Inc. (Updated 03/27/2019)


Vincent Calvez, MD, PhD
Hopital Pitie-Salpetriere
Paris, France

Dr Calvez has served as an advisor or consultant to and has received research grants from Bristol-Myers Squibb, Johnson and Johnson, ViiV Healthcare, and Gilead Sciences, Inc, and is a founder of SkinDermic Pharma. (Updated 3/25/2019)

Roger Paredes, MD, PhD
HIV Unit and IrsiCaixa AIDS Research Institute
Hospital Universitari Germans Trias I Pujol
Badalona, Spain

Dr Paredes has received research grants from ViiV Healthcare and Merck & Co, Inc. (Updated 07/20/18)

Deenan Pillay, MD, PhD
Professor of Virology
University College London
United Kingdom
Director of the Africa Centre for Health and Population Studies
University of KwaZulu Natal
Mtubatuba, South Africa

Dr Pillay has no relevant financial affiliations to disclose. (Updated 07/20/18)

Robert W. Shafer, MD
Assistant Professor
Stanford University
Stanford, California

Dr. Shafer has received grants from Janssen Pharmaceuticals and personal fees from Abbott Diagnostics. (Updated 03/24/19)

Annemarie M. Wensing, MD, PhD
University Medical Center Utrecht
Utrecht, The Netherlands

Dr Wensing has served on advisory boards for CLJI Worldwide, ViiV Healthcare, Merck & Co, Inc, Janssen Pharmaceuticals, and Gilead Sciences, Inc; received grants from Janssen Pharmaceuticals, ViiV Healthcare, and Gilead Sciences, Inc; and received support from Virology Education (conference organizer). (Updated 3/25/2019)

Donna M. Jacobsen, BS
Executive Director/President
International Antiviral Society-USA
San Francisco, California

Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 05/23/19)

Douglas D. Richman, MD
Professor of Pathology and Medicine
University of California San Diego
San Diego, California

Dr Richman has been a consultant to Antiva Biosciences, Gilead Sciences, Inc, and Viriome, Inc. (Updated 05/21/19)